Continuous Rifampicin Therapy Induced Acute Kidney Injury in a Tuberculous Patient: A Case Report

Background: Tuberculosis (TB) presents with productive cough, hemoptysis, chest pain, fever, weight loss, and night sweats. Anti-tuberculosis treatment (ATT) can affect various organs, including the liver and kidneys. ATT-induced acute kidney injury (AKI) presents with fever, rash, nausea, vomiting,...

詳細記述

保存先:
書誌詳細
主要な著者: Muqsit Ali Shaukat (著者), Muhammad Fahad Ali (著者), Ahmed Irtaza (著者), Shehroz Yar Khan (著者), Shad Muhammad Khan (著者), Sohail Babar (著者)
フォーマット: 図書
出版事項: University Library System, University of Pittsburgh, 2024-07-01T00:00:00Z.
主題:
オンライン・アクセス:Connect to this object online.
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8362cfaa6dea4aa89c53687789b4b1e7
042 |a dc 
100 1 0 |a Muqsit Ali Shaukat  |e author 
700 1 0 |a Muhammad Fahad Ali  |e author 
700 1 0 |a Ahmed Irtaza  |e author 
700 1 0 |a Shehroz Yar Khan  |e author 
700 1 0 |a Shad Muhammad Khan   |e author 
700 1 0 |a Sohail Babar  |e author 
245 0 0 |a Continuous Rifampicin Therapy Induced Acute Kidney Injury in a Tuberculous Patient: A Case Report 
260 |b University Library System, University of Pittsburgh,   |c 2024-07-01T00:00:00Z. 
500 |a 10.5195/ijms.2024.1713 
500 |a 2076-6327 
520 |a Background: Tuberculosis (TB) presents with productive cough, hemoptysis, chest pain, fever, weight loss, and night sweats. Anti-tuberculosis treatment (ATT) can affect various organs, including the liver and kidneys. ATT-induced acute kidney injury (AKI) presents with fever, rash, nausea, vomiting, diarrhea, and abdominal pain. It occurs due to type 2 or 3 hypersensitivity and affects individuals who have previously used rifampicin or are currently using it intermittently. Case: An 60-year-old lady was diagnosed with TB and started on ATT. After a few days, she complained of reduced food intake and vomiting, yellow discoloration of the skin, abdominal pain and distention, and limb swelling. She was diagnosed as a case of ATT-induced AKI. She didn't have past exposure to rifampicin and was continuously using it this time. Conclusion: The key learning point from this case is that ATT-induced AKI can develop even when used in a continuous dosing regime and upon first time exposure despite no history of past exposure. This prompts vigilance in monitoring renal function in patients being started on ATT regimen. This is becasuse, ATT-induced AKI poses risk to patient's life and there is a possibility of developing resistance to anti-tuberculous therapy as a result of discontinuation of treatment. Furthermore, our case suggests that, in addition to immune-mediated mechanisms described in literature for ATT-induced AKI, other pathophysiological mechanisms might also be linked to this pathology and need further research for better understanding and optimization of treatment strategies. 
546 |a EN 
690 |a Anti-tuberculosis 
690 |a Rifampicin 
690 |a Isoniazid 
690 |a acute kidney injury 
690 |a Tuberculosis.  
690 |a Medicine (General) 
690 |a R5-920 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n International Journal of Medical Students, Vol 12, Iss 2 (2024) 
787 0 |n http://ijms.info/IJMS/article/view/1713 
787 0 |n https://doaj.org/toc/2076-6327 
856 4 1 |u https://doaj.org/article/8362cfaa6dea4aa89c53687789b4b1e7  |z Connect to this object online.